Several attorneys in the products liability arena say there are significantly fewer testosterone therapy drug cases being filed nationwide than initially expected.
While maintaining that the cases still have multidistrict litigation and mass tort potential, lawyers attribute the relatively small number of cases to the difficulties in litigating “low T” drug claims, especially in linking heart attacks and strokes—the alleged injuries—to the drugs and not other health factors present in men over 50, the primary users of the drugs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
